Walled Lake Planning & Wealth Management LLC Acquires New Position in Sanofi $SNY

Walled Lake Planning & Wealth Management LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 45,885 shares of the company’s stock, valued at approximately $1,892,000.

Several other large investors have also made changes to their positions in the business. Manning & Napier Advisors LLC increased its stake in shares of Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after acquiring an additional 1,194,141 shares during the period. Bank of America Corp DE boosted its holdings in Sanofi by 11.0% in the first quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after purchasing an additional 940,342 shares during the last quarter. Regal Partners Ltd boosted its holdings in Sanofi by 33.2% in the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock valued at $122,639,000 after purchasing an additional 633,782 shares during the last quarter. Royal Bank of Canada grew its position in Sanofi by 17.5% during the 1st quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after purchasing an additional 470,882 shares during the period. Finally, ADAR1 Capital Management LLC grew its position in Sanofi by 399.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company’s stock worth $15,270,000 after purchasing an additional 253,465 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. Wolfe Research started coverage on Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating on the stock. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Berenberg Bank reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of Sanofi in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi Price Performance

SNY opened at $44.34 on Monday. Sanofi has a fifty-two week low of $39.07 and a fifty-two week high of $52.68. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The company has a fifty day moving average of $42.21 and a two-hundred day moving average of $44.35. The stock has a market capitalization of $107.50 billion, a price-to-earnings ratio of 21.95, a PEG ratio of 1.37 and a beta of 0.31.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.24%. The business had revenue of $17.25 billion during the quarter, compared to the consensus estimate of $14.30 billion. During the same quarter in the prior year, the firm posted $2.91 earnings per share. The company’s revenue was up 16.2% compared to the same quarter last year. On average, research analysts expect that Sanofi will post 5.00 earnings per share for the current year.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.